Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Journal of Applied Pharmaceutical Research
Ananta Choudhury, Ananta
Unknown Affiliation
Medicine & Pharmacology

Published : 24 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 24 Documents
Search

 1   2   3 
Autism: a curse on today’s society Sarkar, Snehashis; Choudhury, Ananta; Saha, Suman; Dey, Biplab Kumar
Journal of Applied Pharmaceutical Research Vol. 8 No. 1 (2020)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (353.39 KB) | DOI: 10.18231/j.joapr.2019.v.8.i.1.001

Abstract

Autism is a group of neurodevelopment disorders characterized by impaired communication, impaired social interaction and restricted, repetitive and stereotyped patterns of behaviours or interests in the first 3 years of life. It shows a strong male bias and found four times more in males than in females. According to a study in the US, in 2014, overall 1.68% of victims were reported to have Autism Spectrum Disorder (ASD), whereas the percentage was increased by 15% and 150% respectively over the year 2012 and 2000. Numerous genes have been discovered that have roles in ASD but still a good understanding of the pathophysiological process of ASD is not established. ASD costs are estimated to be approximately $250 billion annually in the U.S. Moreover, it is suggested that by 2025, ASD costs will rise to over $450 billion. Thus, the financial burden on families is increasing. There is no effective screening tool for proper diagnosis is available. Based on Infant Toddler Checklist (ITC) and Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) some tests like ADOS-G, ADI-R, CARS etc. are used for diagnosis. There are medications to cure symptoms but no single medication for ASD. However, some therapies (like ABA- Applied Behavioural Analysis, DTT- Discrete Trial Training, and Symptomatic treatments, etc.) are there that show positive responses towards improvement from a disease state. Some crucial advancement has been achieved in the last decades. Here in the work we have focused on the diagnostic methods and treatment available for the symptoms of Autism. So, it can be said that the day is not too far away when the remedy to cut the curse of autism will be in our hands.
Liposome: a carrier for effective drug delivery Choudhury, Ananta; Sonowal, Kashmiri; Laskar, Rahela E; Deka, Debasish; Dey, Biplab Kumar
Journal of Applied Pharmaceutical Research Vol. 8 No. 1 (2020)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (911.688 KB) | DOI: 10.18231/j.joapr.2019.v.8.i.1.003

Abstract

Liposomes are the spherical vesicles containing one or more phospholipid bilayer, which was first described in the middle of 60s by Bangham. The bilayer vesicles are considered as an efficient carrier for drug delivery, diagnostic agents, and also an effective tool for vaccine delivery. Liposome has been used as a potential carrier for several diseases from cardiovascular disease to bacterial infection and also it has the ability to reducing the toxicity of highly potent drugs and simultaneously utilized to improve pharmacokinetics and therapeutic efficacy. A liposome is a formulation which has the capacity to overcome with the limitation of conventional therapies. For the delivery of liposome ocular and inhalation route are some advanced technology. In poorly water soluble substance pulmonary delivery is very much useful. However liposome based vaccines have been demonstrated in clinical trials and further progress in human trails. This review discusses the mechanism of action, Method of preparation, evaluation, application of liposomal drug delivery system along with the recent developments some of the commercially available products.
Current trends and future perspectives of natural polymer loaded nanoparticle based drug delivery system for the management of inflammatory bowel disease Basak, Ankita; Ghosh, Soumyadip; Ganguly, Debgopal; Garain, Soukat; Ghosh, Riya; Choudhury, Ananta; Deka, Himangshu; Sarmah, Jahnabi
Journal of Applied Pharmaceutical Research Vol. 11 No. 4 (2023)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18231/j.joapr.2023.11.4.1.9

Abstract

Targeting the drug delivery system is very tough nowadays due to premature drug release at the upper GIT tract and altered pH conditions. Colon-specific drug delivery systems can overcome that problem using different polymer combinations. A nanoparticulate drug delivery system is the prominent dosage form that impacts the bioavailability and requires a low dose to excrete the therapeutic efficacy. All nanoscience and nanotechnology are applications of Nanometrology, the science of measurements at the nanoscale. NPDDSs were primarily developed to combine the colloidal stability of solid particle suspensions in biological fluids and the solubilizing properties of liquids. An ideal drug-delivery system possesses two elements: the ability to target and control the drug release. Colloidal drug carriers offer a number of potential advantages as delivery systems, such as better bioavailability for poorly soluble drugs. Researchers have created various sophisticated and multifunctional nanocarrier systems that can transport pharmaceuticals in a targeted, sustained, and regulated manner to provide therapeutic medications that are safer and more effective, particularly to ulcerative colitis. These innovative technologies are improving the pharmacokinetic profile of pharmaceuticals, increasing their systemic circulation, and decreasing the frequency of pharmacological side effects. The review focuses on the current trend and future perspectives of natural polymer-based-loaded nanoparticle-based drug delivery systems for the management of inflammatory bowel disease.
Comprehensive review of breast cancer risk factors, diagnosis, screening, and treatment methods Hoque, Nurjamal; Choudhury, Ananta; Baishya, Dhiraj; Deka, Himangshu
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.606

Abstract

Background: Breast cancer is one of the leading causes of cancer-related deaths among women, accounting for 11.7% of all cancer cases and approximately 685,000 deaths worldwide in 2020. Its multifactorial etiology includes genetic, hormonal, and lifestyle-related risk factors with significant implications for diagnosis and treatment. Understanding these factors and the latest advancements in screening and therapeutic approaches is essential for improving patient outcomes. Methodology: This review synthesizes findings from peer-reviewed articles, clinical trials, and meta-analyses. The focus is on identifying key risk factors for breast cancer, evaluating the effectiveness of current diagnostic methods, and examining the latest treatment strategies, including personalized medicine. Data were collected from PubMed, Scopus, and Google Scholar databases. Results and Discussion: The review highlights major risk factors, including BRCA1/BRCA2 mutations, which contribute to a 45-65% lifetime risk, as well as hormonal influences and lifestyle factors like obesity and alcohol consumption. Targeted therapies, such as HER2 inhibitors (e.g., trastuzumab) and hormone therapies (e.g., tamoxifen), have significantly improved survival rates. Emerging treatments like immunotherapy and PARP inhibitors are also promising for aggressive and metastatic cases. Conclusion: Breast cancer continues to pose a significant health challenge, but advancements in risk assessment, early detection, and personalized treatment offer hope for better outcomes. Continued research and refining diagnostic and therapeutic approaches are essential for reducing breast cancer mortality and enhancing patient quality of life.  
Co-Authors Ahmed, Raju Amit Roy, Amit Baishya, Dhiraj Barakoti, Himal Basak, Ankita Changmai, Arabinda Changmai, Arabinda Deka, Debasish Deka, Himangshu Deka, Manoj Kumar Deka, Manoj Kumar Devnarayan Sinha, Devnarayan Dewan, Manjima Dey, Biplab K. Dey, Biplab Kumar Dey, Biplab Kumar Ganguly, Debgopal Garain, Soukat Ghosh, Riya Ghosh, Soumyadip Goswami, Priyanka Goswami, Priyanka Hoque, Nurjamal Islam, Rajibul Islam, Rajibul Islam, Tofiqul Islam, Tofiqul Jyotirmoy Deb, Jyotirmoy Khongmalai, Everlasting Khongmalai, Everlasting Laskar, Rahela E Laskar, Rahela Eyachmin Neman Sinha, Neman Nongsiang, Dibarlan Nongsiang, Dibarlan Pragya Baghel, Pragya Ranabir Chanda, Ranabir Reema Verma, Reema Renthlei, Lalmalsawmi Roy, Am Saharia, Bhargab Jyoti Saharia, Bhargab Jyoti Sanjib Bahadur, Sanjib Sarkar, Bapi Ray Sarkar, Bapi Ray Sarkar, Snehashis Sarmah, Jahnabi Saurabh Sahu, Saurabh Sen, Saikat Sen, Saikat Shailendra Wadhwa, Shailendra Sonowal, Kashmiri Suchita Gupta, Suchita Sujoy Das, Sujoy Suman Saha, Suman SWATI VERMA Vinod Rathor, Vinod